focus -WSS

focus

author：comprehensive 2025-10-01 00:07:00 - browse：22933

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

hotspot

explore

WSS

Venture capitalist Bob Kocher on the state of digital health

HIV vaccine remains elusive. Immunologists keep trying new ideas

When prostate cancer spreads, where it goes matters

Let's speed up science by embracing open access publishing

Let's speed up science by embracing open access publishing

Data integrity in scientific journals requires "effort" by publishers, institutions

focus

focus

focus

23andMe had bad news about my health. I wish a person had delivered it

Criminal prosecution for violating HIPAA: an emerging threat

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Military medical care influenced by rank and race, new study finds

How one medical school became remarkably diverse

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Cancer drug shortages should be causing more outrage

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

What does generative AI mean for health care? We asked experts

NVIDIA and Google execs on the future of AI and drug discovery

Wikipedia

Military medical care influenced by rank and race, new study finds

Let's speed up science by embracing open access publishing

Cytokinetics CEO stresses company can launch heart drug on its own

Ultragenyx gene therapy for rare liver ailment succeeds in late

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

The Pandemic Treaty must support building strong health systems

focus

hotspot

explore

entertainment